MedPath

The analysis of Eribulin in patients with unresectable breast cancer, retorospective multicenter study

Not Applicable
Conditions
HER2-negative Unresectable breast cancer
Registration Number
JPRN-UMIN000014158
Lead Sponsor
Kobe City Medical Center General Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
150
Inclusion Criteria

Not provided

Exclusion Criteria

none.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
overall survival
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath